| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | plcH |
| Uniprot No | P06200 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 51-436aa |
| 氨基酸序列 | VQHVVILMQENRSFDHYFGHLNGVRGFNDPRALKRQDGKPVWYQNYKYEF SPYHWDTKVTSAQWVSSQNHEWSAFHAIWNQGRNDKWMAVQYPEAMGYFK RGDIPYYYALADAFTLCEAYHQSMMGPTNPNRLYHMSGRAAPSGDGKDVH IGNDMGDGTIGASGTVDWTTYPERLSAAGVDWRVYQEGGYRSSSLWYLYV DAYWKYRLQEQNNYDCNALAWFRNFKNAPRDSDLWQRAMLARGVDQLRKD VQENTLPQVSWIVAPYCYCEHPWWGPSFGEYYVTRVLEALTSNPEVWART VFILNYDEGDGFYDHASAPVPPWKDGVGLSTVSTAGEIEVSSGLPIGLGH RVPLIAISPWSKGGKVSAEVFDHTSVLRFLERRFGV |
| 预测分子量 | 64 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于铜绿假单胞菌(Pseudomonas aeruginosa)plcH重组蛋白的参考文献示例(内容为虚构，供格式参考)：
1. **文献名称**: "Cloning and Characterization of the plcH Gene from Pseudomonas aeruginosa"
**作者**: Berka, T.R., Vasil, M.L.
**摘要**: 本研究首次报道了plcH基因的克隆及重组蛋白表达，证明其编码的磷脂酶C在细菌膜损伤和宿主细胞裂解中起关键作用，重组蛋白在体外表现出溶血活性和磷脂降解能力。
2. **文献名称**: "Role of Recombinant PlcH in Pseudomonas aeruginosa Virulence"
**作者**: Ostroff, R.M., et al.
**摘要**: 通过重组plcH蛋白实验，发现该酶通过降解肺表面活性物质促进肺部感染，并揭示了其与宿主免疫逃逸相关的分子机制，为抗感染治疗提供潜在靶点。
3. **文献名称**: "Expression and Purification of Functional PlcH Recombinant Protein for Vaccine Development"
**作者**: Smith, J., et al.
**摘要**: 开发了一种高效的大肠杆菌表达系统，获得高纯度plcH重组蛋白，动物实验显示其作为疫苗候选抗原可显著降低铜绿假单胞菌感染的致死率。
注：以上为模拟文献，实际研究需通过PubMed/Google Scholar检索关键词如"Pseudomonas aeruginosa plcH recombinant"获取真实文献。
**Background of PLCζ Recombinant Protein**
Phospholipase C zeta (PLCζ), a sperm-specific phospholipase, plays a critical role in activating oocyte development during fertilization. Upon sperm-egg fusion, PLCζ is introduced into the oocyte cytoplasm, where it triggers calcium (Ca²⁺) oscillations essential for egg activation, embryo development, and early embryogenesis. Unlike other phospholipase C isoforms, PLCζ lacks a pleckstrin homology (PH) domain but contains EF-hand motifs and a C2 domain, which are vital for its enzymatic activity and intracellular localization.
Deficiencies or mutations in PLCζ are linked to male infertility, particularly in cases of oocyte activation failure following intracytoplasmic sperm injection (ICSI). This has driven interest in developing recombinant PLCζ as a therapeutic agent. Recombinant PLCζ is typically produced using expression systems like *E. coli* or mammalian cells, followed by purification to ensure bioactivity. Studies demonstrate that exogenous recombinant PLCζ can rescue Ca²⁺ oscillations in PLCζ-deficient sperm, restoring fertilization potential.
Research also explores its application in assisted reproductive technologies (ART), such as improving ICSI outcomes for infertile couples. However, challenges remain, including optimizing protein stability, delivery methods, and understanding dose-dependent effects. Additionally, structural studies of recombinant PLCζ aim to clarify its activation mechanism and interactions with oocyte components.
Overall, PLCζ recombinant protein represents a promising biotherapeutic tool for addressing certain forms of male infertility and enhancing ART success, though further clinical validation is required to ensure safety and efficacy.
×
